Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% - Here's What HappenedMarket Beat·1 day ago, 01:20 AMKLRS-3.01%
Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statementPUBT·2 days ago, 03:02 PMKLRS-3.01%
Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statementPUBT·Jul 27 at 03:05 PMKLRS-3.01%
Kalaris names Liisa Bayko CFO and Amy Vandekop interim principal accounting officerTradingView·Jul 20 at 07:13 AMKLRS-3.01%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Jul 17 at 12:05 PMAPLM-1.68%APLMW-1.24%
Kalaris Therapeutics shares are trading higher after the company announced additional data from its Phase 1a single ascending dose trial of TH103 in neovascular age-related macular degeneration.benzinga_article·Jul 17 at 09:58 AMKLRS-3.01%
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts | KLRS Stock NewsStockTitan·Jul 16 at 10:00 PMKLRS-3.01%
